Study summary
A cathepsin C blocker showed a dose-dependent reduction in flare-ups
0.66hazard ratio for first flare-up at 2.5 mg
What was tested
BI 1291583, a once-daily pill that blocks cathepsin C (the same target as DPP-1), at three doses against placebo for 24 to 48 weeks.
What they found
- Benefit increased with dose, meeting the main goal.
- At 2.5 mg, the risk of a first flare-up was 34% lower (hazard ratio 0.66), though individual doses were not statistically significant.
- Safety was similar to placebo.
What it means
Led to the phase 3 AIRTIVITY trial.
Last reviewed 2026-11-16 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.